2024
2023
Year Ended December 31, 2023
Quarter Ended September 30, 2023
2022
Year Ended December 31, 2022
Quarter Ended September 30, 2022
Quarter Ended June 30, 2022
Quarter Ended March 31, 2022
2021
Year Ended December 31, 2021
Quarter Ended September 30, 2021
Quarter Ended June 30, 2021
Quarter Ended March 31, 2021
2020
Year Ended December 31, 2020
Quarter Ended September 30, 2020
Quarter Ended June 30, 2020
Quarter Ended March 31, 2020
2019
Year Ended December 31, 2019
Quarter Ended September 30, 2019
Quarter Ended June 30, 2019
Quarter Ended March 31, 2019
2018
Year Ended December 31, 2018
Quarter Ended September 30, 2018
Quarter Ended June 30, 2018
Year Ended December 31, 2022
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com